Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Astermark

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 24, 2003
When to start and when to stop primary prophylaxis in patients with severe haemophiliaJ Astermark
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 3, 2011
The Arosenius FundJ Astermark
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 26, 2012
Prevention and prediction of inhibitor riskJ Astermark
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 11, 2006
Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophiliaJ Astermark
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 21, 2009
Inhibitor development: patient-determined risk factorsJ Astermark
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 25, 2006
Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factorsJ Astermark
Vox Sanguinis|October 26, 1999
Malmö International Brother Study (MIBS): an international survey of brother pairs with haemophiliaJ Astermark, E Berntorp
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 8, 2018
The role of the laboratory in diagnosis and management of inhibitory antibodies in haemophiliaK Strandberg, J Astermark
The Journal of Biological Chemistry|February 5, 1991
The epidermal growth factor-like domains of factor IX. Effect on blood clotting and endothelial cell binding of a fragment containing the epidermal growth factor-like domains linked to the gamma-carboxyglutamic acid regionJ Astermark, J Stenflo
Lakartidningen|October 23, 1996
[Antithrombin III concentrate seeks its therapeutic role. Be careful and wait for the results of the studies!]J Astermark, S Lethagen, E Berntorp
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 24, 2003
When to start and when to stop primary prophylaxis in patients with severe haemophiliaJ Astermark
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 3, 2011
The Arosenius FundJ Astermark
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 26, 2012
Prevention and prediction of inhibitor riskJ Astermark
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 11, 2006
Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophiliaJ Astermark
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 21, 2009
Inhibitor development: patient-determined risk factorsJ Astermark
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 25, 2006
Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factorsJ Astermark
Vox Sanguinis|October 26, 1999
Malmö International Brother Study (MIBS): an international survey of brother pairs with haemophiliaJ Astermark, E Berntorp
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 8, 2018
The role of the laboratory in diagnosis and management of inhibitory antibodies in haemophiliaK Strandberg, J Astermark
The Journal of Biological Chemistry|February 5, 1991
The epidermal growth factor-like domains of factor IX. Effect on blood clotting and endothelial cell binding of a fragment containing the epidermal growth factor-like domains linked to the gamma-carboxyglutamic acid regionJ Astermark, J Stenflo
Lakartidningen|October 23, 1996
[Antithrombin III concentrate seeks its therapeutic role. Be careful and wait for the results of the studies!]J Astermark, S Lethagen, E Berntorp
Pageof 8